Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.100
+0.060 (5.77%)
At close: Sep 17, 2026, 4:00 PM EDT
1.140
+0.040 (3.64%)
After-hours: Sep 17, 2026, 4:15 PM EDT
Annovis Bio Employees
Annovis Bio had 7 employees as of December 31, 2025. The number of employees decreased by 8 or -53.33% compared to the previous year.
Employees
7
Change (1Y)
-8
Growth (1Y)
-53.33%
Revenue / Employee
n/a
Profits / Employee
-$7,074,895
Market Cap
46.87M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | -8 | -53.33% | 7 | 0 |
| Dec 31, 2024 | 15 | -1 | -6.25% | 8 | 7 |
| Dec 31, 2023 | 16 | 11 | 220.00% | 6 | 10 |
| Dec 31, 2022 | 5 | 2 | 66.67% | 5 | 0 |
| Dec 31, 2021 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 113 |
| Clene | 79 |
| Seres Therapeutics | 66 |
| Mereo BioPharma Group | 39 |
| Elicio Therapeutics | 33 |
| Tevogen | 18 |
| Instil Bio | 17 |
| Werewolf Therapeutics | 14 |
ANVS News
- 6 days ago - Annovis Bio Proxy statement: Proxy filing - Filings
- 15 days ago - Annovis Bio Transcript: Investor update - Transcripts
- 20 days ago - Annovis Bio price target lowered to $7 from $8 at Roth Capital - TheFly
- 23 days ago - Annovis to Host Corporate Update Webinar on September 2, 2026 - GlobeNewsWire
- 23 days ago - Annovis Bio Proxy statement: Proxy filing - Filings
- 4 weeks ago - Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - GlobeNewsWire
- 4 weeks ago - Annovis Bio Earnings release: Q2 2026 - Filings
- 4 weeks ago - Annovis Bio Quarterly report: Q2 2026 - Filings